# Fulcrum Therapeutics, Inc.: overview FULC · Nasdaq · CIK 1680581 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fulc.md) · [Financials](/companies/fulc/financials.md) · [Filings](/companies/fulc/filings.md) · [Insiders](/companies/fulc/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-065197.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Feb 24, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-065197). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-25-254633.md) | [0.0 d](/filings/0001193125-26-065197.md) | not reported | [0.0](/filings/0000950170-25-099407.md) | [0.0](/filings/0001193125-25-254633.md) | [0.0 d](/filings/0001193125-26-065197.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.35)](/filings/0001193125-25-254633.md) | not reported | [(0.28)](/filings/0001193125-26-178814.md) | [(0.28)](/filings/0001193125-26-326098.md) | [(0.31)](/filings/0001193125-25-254633.md) | not reported | [(0.25)](/filings/0001193125-26-178814.md) | [(0.34)](/filings/0001193125-26-326098.md) | | Free cash flow | $m | [(19.1) d](/filings/0001193125-25-254633.md) | [(17.0) d](/filings/0001193125-26-065197.md) | [(15.3)](/filings/0001193125-26-178814.md) | [(13.9) d](/filings/0001193125-26-326098.md) | [(14.3) d](/filings/0001193125-25-254633.md) | [(17.0) d](/filings/0001193125-26-065197.md) | [(18.8)](/filings/0001193125-26-178814.md) | [(16.1) d](/filings/0001193125-26-326098.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [19.2](/filings/0000950170-23-029693.md) | [6.3](/filings/0000950170-24-021074.md) | [2.8](/filings/0000950170-25-026068.md) | [80.0](/filings/0001193125-26-065197.md) | [0.0](/filings/0001193125-26-065197.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(423.0%)](/filings/0000950170-23-029693.md) | [(1774.9%)](/filings/0000950170-24-021074.md) | [(3945.2%)](/filings/0000950170-25-026068.md) | [(27.4%)](/filings/0001193125-26-065197.md) | not reported | | Net margin | % | [(421.9%)](/filings/0000950170-23-029693.md) | [(1732.4%)](/filings/0000950170-24-021074.md) | [(3470.1%)](/filings/0000950170-25-026068.md) | [(12.2%)](/filings/0001193125-26-065197.md) | not reported | | Diluted EPS | $ per share | [(2.29)](/filings/0000950170-23-029693.md) | [(2.44)](/filings/0000950170-24-021074.md) | [(1.59)](/filings/0000950170-25-026068.md) | [(0.16)](/filings/0001193125-26-065197.md) | [(1.18)](/filings/0001193125-26-065197.md) | | Free cash flow | $m | [(80.2)](/filings/0000950170-23-029693.md) | [(99.0)](/filings/0000950170-24-021074.md) | [(91.5)](/filings/0000950170-25-026068.md) | [(2.5)](/filings/0001193125-26-065197.md) | [(60.4)](/filings/0001193125-26-065197.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fulc/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2019-07-22 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 93,750 | $16.00 | $1.5m | [Form 4](/filings/0000899243-19-020073.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $32.3m | 8,824,259 | | Added +3,433,666 | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $24.0m | 6,549,866 | | New +6,549,866 | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $23.9m | 6,521,412 | | New +6,521,412 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $20.0m | 5,475,040 | | Added +2,425,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $20.0m | 5,475,040 | | Added +2,425,000 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $13.5m | 3,680,921 | | Reduced −2,880,190 | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $11.1m | 3,044,385 | | Added +1,421,104 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $9.9m | 2,704,505 | | Added +1,412,019 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.9m | 2,697,216 | | Added +4,268 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $8.1m | 2,217,498 | | Added +1,907,081 | ## Recent filings [All 502 filings](/companies/fulc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-17 | 08:30 ET | [8-K](/filings/0001193125-26-353278.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-353278 | | 2026-08-10 | 08:43 ET | [8-K](/filings/0001193125-26-341385.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-341385 | | 2026-07-30 | 16:05 ET | [10-Q](/filings/0001193125-26-326098.md) | Quarterly report, period 2026-06-30 | 0001193125-26-326098 | | 2026-06-25 | 16:32 ET | [8-K](/filings/0001193125-26-282873.md) | 5.07 Shareholder vote results | 0001193125-26-282873 | | 2026-06-11 | 16:30 ET | [8-K](/filings/0001193125-26-267659.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-267659 | | 2026-06-04 | 16:05 ET | [8-K](/filings/0001193125-26-257376.md) | 2.05 Exit or disposal costs; 8.01 Other events | 0001193125-26-257376 | | 2026-06-01 | 16:05 ET | [8-K](/filings/0001193125-26-251394.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-251394 | | 2026-04-30 | 16:06 ET | [DEF 14A](/filings/0001193125-26-197196.md) | Proxy statement, period 2026-06-24 | 0001193125-26-197196 | | 2026-04-27 | 07:10 ET | [10-Q](/filings/0001193125-26-178814.md) | Quarterly report, period 2026-03-31 | 0001193125-26-178814 | | 2026-04-27 | 07:05 ET | [8-K](/filings/0001193125-26-178806.md) | 1.02 Termination of a material agreement; 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-178806 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-065197.md), filed Feb 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1680581 - Tickers: FULC - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:11 ET. No prices; not investment advice.